First Trust Advisors L.P. Announces Distribution for First Trust Income Opportunities ETF

First Trust Advisors L.P. Announces Distribution for First Trust Income Opportunities ETF

WHEATON, Ill.–(BUSINESS WIRE)–
First Trust Advisors L.P. (“FTA”) announces the declaration of the monthly distribution for First Trust Income Opportunities ETF, advised by FTA.

The following dates apply to today’s distribution declaration:

Expected Ex-Dividend Date:

October 12, 2022

Record Date:

October 13, 2022

Payable Date:

October 31, 2022

Ticker

Exchange

Fund Name

Frequency

Ordinary

Income

Per Share

Amount

 

ACTIVELY MANAGED EXCHANGE-TRADED FUNDS

 

First Trust Exchange-Traded Fund VIII

FCEF

Nasdaq

First Trust Income Opportunities ETF

Monthly

$0.1175

FTA is a federally registered investment advisor and serves as the Fund’s investment advisor. FTA and its affiliate First Trust Portfolios L.P. (“FTP”), a FINRA registered broker-dealer, are privately-held companies that provide a variety of investment services. FTA has collective assets under management or supervision of approximately $178 billion as of September 30, 2022 through unit investment trusts, exchange-traded funds, closed-end funds, mutual funds and separate managed accounts. FTA is the supervisor of the First Trust unit investment trusts, while FTP is the sponsor. FTP is also a distributor of mutual fund shares and exchange-traded fund creation units. FTA and FTP are based in Wheaton, Illinois.

You should consider the investment objectives, risks, charges and expenses of a Fund before investing. Prospectuses for the Funds contain this and other important information and are available free of charge by calling toll-free at 1-800-621-1675 or visiting https://www.ftportfolios.com. A prospectus should be read carefully before investing.

Principal Risk Factors: Risks are inherent in all investing. Certain risks applicable to the fund are identified below. The material risks of investing in the fund are spelled out in its prospectus, statement of additional information and other regulatory filings. The order of the below risk factors does not indicate the significance of any particular risk factor.

Past performance is no assurance of future results. Investment return and market value of an investment in a Fund will fluctuate. Shares, when sold, may be worth more or less than their original cost.

A Fund’s shares will change in value, and you could lose money by investing in a Fund. An investment in a Fund is not a deposit of a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency. There can be no assurance that a Fund’s investment objectives will be achieved. An investment in a Fund involves risks similar to those of investing in any portfolio of equity securities traded on exchanges. The risks of investing in each Fund are spelled out in its prospectus, shareholder report, and other regulatory filings.

Investors buying or selling fund shares on the secondary market may incur customary brokerage commissions. Market prices may differ to some degree from the net asset value of the shares. Investors who sell fund shares may receive less than the share’s net asset value. Shares may be sold throughout the day on the exchange through any brokerage account. However, unlike mutual funds, shares may only be redeemed directly from a fund by authorized participants in very large creation/redemption units. If a fund’s authorized participants are unable to proceed with creation/ redemption orders and no other authorized participant is able to step forward to create or redeem, fund shares may trade at a discount to a fund’s net asset value and possibly face delisting.

A fund’s shares will change in value, and you could lose money by investing in a fund. One of the principal risks of investing in a fund is market risk. Market risk is the risk that a particular stock owned by a fund, fund shares or stocks in general may fall in value. There can be no assurance that a fund’s investment objective will be achieved. In February 2022, Russia invaded Ukraine which has caused and could continue to cause significant market disruptions and volatility within the markets in Russia, Europe, and the United States. The hostilities and sanctions resulting from those hostilities could have a significant impact on certain fund investments as well as fund performance. The COVID-19 global pandemic and the ensuing policies enacted by governments and central banks have caused and may continue to cause significant volatility and uncertainty in global financial markets. While the U.S. has resumed “reasonably” normal business activity, many countries continue to impose lockdown measures. Additionally, there is no guarantee that vaccines will be effective against emerging variants of the disease.

In managing a fund’s investment portfolio, the portfolio managers will apply investment techniques and risk analyses that may not have the desired result.

All or a portion of a fund’s otherwise exempt-interest dividends may be taxable to those shareholders subject to the federal and state alternative minimum tax.

Asset-backed securities are a type of debt security and are generally not backed by the full faith and credit of the U.S. government and are subject to the risk of default on the underlying asset or loan, particularly during periods of economic downturn.

A fund that effects all or a portion of its creations and redemptions for cash rather than in-kind may be less tax-efficient.

Because the shares of CEFs cannot be redeemed upon demand, shares of many CEFs will trade on exchanges at market prices rather than net asset value, which may cause the shares to trade at a price greater than NAV (premium) or less than NAV (discount). A fund may invest in the shares of CEFs which involves additional expenses that would not be present in a direct investment in the underlying funds. In addition, a fund’s investment performance and risks may be related to the investment performance and risks of the underlying funds.

Commodity prices can have significant volatility, and exposure to commodities can cause the value of a fund’s shares to decline or fluctuate in a rapid and unpredictable manner.

A convertible security is exposed to risks associated with both equity and debt securities. The value of convertibles may rise and fall with the market value of the underlying stock or vary with changes in interest rates and credit quality of the issuer.

A fund may be subject to the risk that a counterparty will not fulfill its obligations which may result in significant financial loss to a fund.

Covenant-lite loans contain fewer maintenance covenants than traditional loans and may not include terms that allow the lender to monitor the financial performance of the borrower and declare a default if certain criteria are breached. This may hinder a fund’s ability to mitigate problems and increase a fund’s exposure to losses on such investments.

A fund is susceptible to operational risks through breaches in cyber security. Such events could cause a fund to incur regulatory penalties, reputational damage, additional compliance costs associated with corrective measures and/or financial loss.

Investments in debt securities subject a fund to call risk, credit risk, extension risk, income risk, inflation risk, interest rate risk, liquidity risk, prepayment risk, valuation risk and zero coupon risk. These risks could result in a decline in a security’s value and/or income, increased volatility as interest rates rise or fall and have an adverse impact on a fund’s performance.

The use of derivatives instruments involves different and possibly greater risks than investing directly in securities including counterparty risk, valuation risk, volatility risk, and liquidity risk. Further, losses because of adverse movements in the price or value of the underlying asset, index or rate may be magnified by certain features of the derivatives.

Distressed securities are speculative and often illiquid or trade in low volumes and thus may be more difficult to value and pose a substantial risk of default.

Companies that issue dividend-paying securities are not required to continue to pay dividends on such securities. Therefore, there is a possibility that such companies could reduce or eliminate the payment of dividends in the future.

A fund may invest in the shares of other ETFs, which involves additional expenses that would not be present in a direct investment in the underlying funds. In addition, a fund’s investment performance and risks may be related to the investment performance and risks of the underlying funds.

Floating rate securities are structured so that the security’s coupon rate fluctuates based upon the level of a reference rate. As a result, the coupon on floating rate securities will generally decline in a falling interest rate environment, causing a fund to experience a reduction in the income it receives from the security. A floating rate security’s coupon rate resets periodically according to the terms of the security. Consequently, in a rising interest rate environment, floating rate securities with coupon rates that reset infrequently may lag behind the changes in market interest rates.

High yield securities, or “junk” bonds, are less liquid and are subject to greater market fluctuations and risk of loss than securities with higher ratings, and therefore, are considered to be highly speculative.

As inflation increases, the present value of the Fund’s assets and distributions may decline.

An underlying fund may invest in inverse floating rate securities which create effective leverage and thus, the value of the inverse floater will increase and decrease to a significantly greater extent. Custodial receipt trusts may issue inverse floater securities and if an underlying fund were to hold inverse floaters issued by custodial receipt trusts, the underlying fund would be subject to the risks of inverse floaters.

A fund’s investment in other investment companies is restricted by federal securities laws which limits the size of the position a fund can take in another investment company. These limitations may prevent a fund from purchasing shares of an investment company that it may have otherwise purchased.

Large capitalization companies may grow at a slower rate than the overall market.

Leverage may result in losses that exceed the mount originally invested and may accelerate the rates of losses. Leverage tends to magnify, sometimes significantly, the effect of any increase or decrease in a fund’s exposure to an asset or class of assets and may cause the value of a fund’s shares to be volatile and sensitive to market swings.

To the extent a fund invests in floating or variable rate obligations that use the London Interbank Offered Rate (“LIBOR”) as a reference interest rate, it is subject to LIBOR Risk. The United Kingdom’s Financial Conduct Authority, which regulates LIBOR, has ceased making LIBOR available as a reference rate over a phase-out period that began December 31, 2021. There is no assurance that any alternative reference rate, including the Secured Overnight Financing Rate (“SOFR”) will be similar to or produce the same value or economic equivalence as LIBOR or that instruments using an alternative rate will have the same volume or liquidity. The unavailability or replacement of LIBOR may affect the value, liquidity or return on certain fund investments and may result in costs incurred in connection with closing out positions and entering into new trades. Any potential effects of the transition away from LIBOR on a fund or on certain instruments in which a fund invests can be difficult to ascertain, and they may vary depending on a variety of factors, and they could result in losses to a fund.

Certain fund investments may be subject to restrictions on resale, trade over-the-counter or in limited volume, or lack an active trading market. Illiquid securities may trade at a discount and may be subject to wide fluctuations in market value.

Master limited partnerships (MLPs) are subject to certain risks, including price and supply fluctuations caused by international politics, energy conservation, taxes, price controls, and other regulatory policies of various governments. In addition, there is the risk that MLPs could be taxed as corporations, resulting in decreased returns from such MLPs.

Mortgage-related securities are more susceptible to adverse economic, political or regulatory events that affect the value of real estate. They are also subject to the risk that the rate of mortgage prepayments decreases, which extends the average life of a security and increases the interest rate exposure.

Participation interests in municipal leases pose special risks because many leases and contracts contain “non-appropriation” clauses that provide that the governmental issuer has no obligation to make future payments under the lease or contract unless money is appropriated for this purpose by the appropriate legislative body.

The values of municipal securities may be adversely affected by local political and economic conditions and developments. Income from municipal securities could be declared taxable because of, among other things, unfavorable changes in tax laws, adverse interpretations by the Internal Revenue Service or state tax authorities, or noncompliant conduct of an issuer.

Inventories of municipal securities have decreased in recent years and some municipal securities may have resale restrictions lessening the ability to make a market in these securities. This reduction in market making capacity has the potential to decrease a fund’s ability to buy or sell municipal securities and increase price volatility and trading costs.

There is no assurance that a fund will be able to sell a portfolio security at the price established by a pricing service, which could result in a loss to a fund.

Securities of non-U.S. issuers are subject to additional risks, including currency fluctuations, political risks, withholding, the lack of liquidity, the lack of adequate financial information, and exchange control restrictions impacting non-U.S. issuers.

A fund and a fund’s advisor may seek to reduce various operational risks through controls and procedures, but it is not possible to completely protect against such risks. The fund also relies on third parties for a range of services, including custody, and any delay or failure related to those services may affect the fund’s ability to meet its objective.

Preferred securities combine some of the characteristics of both common stocks and bonds. Preferred stocks are typically subordinated to other debt instruments in terms of priority to corporate income, and therefore will be subject to greater credit risk than those debt instruments.

The securities held in an escrow fund pledged to pay the principal and interest of a pre-refunded bond do not guarantee the price of the bond.

Private activity bonds can have a substantially different credit profile than the municipality or public authority that issued them and may be negatively impacted by conditions affecting the general credit of the private enterprise or the project itself.

REITs are subject to certain risks, including changes in the real estate market, vacancy rates and competition, volatile interest rates and economic recession.

Companies that issue loans tend to be highly leveraged and thus are more susceptible to the risks of interest deferral, default and/or bankruptcy. Loans are usually rated below investment grade but may also be unrated. As a result, the risks associated with these loans are similar to the risks of high yield fixed income instruments. The senior loan market has seen a significant increase in loans with weaker lender protections which may impact recovery values and/or trading levels in the future.

A fund with significant exposure to a single asset class, country, region, industry, or sector may be more affected by an adverse economic or political development than a broadly diversified fund.

Securities of small- and mid-capitalization companies may experience greater price volatility and be less liquid than larger, more established companies.

Investments in sovereign bonds involve special risks because the governmental authority that controls the repayment of the debt may be unwilling or unable to repay the principal and/or interest when due. In times of economic uncertainty, the prices of these securities may be more volatile than those of corporate debt or other government debt obligations.

Trading on the exchange may be halted due to market conditions or other reasons. There can be no assurance that the requirements to maintain the listing of a fund on the exchange will continue to be met or be unchanged.

Securities issued or guaranteed by federal agencies and U.S. government sponsored instrumentalities may or may not be backed by the full faith and credit of the U.S. government.

A fund may hold securities or other assets that may be valued on the basis of factors other than market quotations. This may occur because the asset or security does not trade on a centralized exchange, or in times of market turmoil or reduced liquidity. Portfolio holdings that are valued using techniques other than market quotations, including “fair valued” assets or securities, may be subject to greater fluctuation in their valuations from one day to the next than if market quotations were used. There is no assurance that a fund could sell or close out a portfolio position for the value established for it at any time.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.

The Securities and Exchange Commission (“SEC”) has adopted Rule 12d1-4 under the Investment Company Act of 1940 (the “1940 Act”) which the funds must comply with in order to invest in shares of other investment companies (“acquired funds”) beyond the statutory limits of Section 12 of the 1940 Act. Rule 12d1-4 permits a fund to invest beyond the statutory limits subject to a set of new conditions, including limits on control and voting of acquired funds’ shares, evaluations and findings by the fund’s investment adviser, fund investing agreements, and limits on most three-tier fund structures. Rule 12d1-4 replaces certain exemptive relief and no-action letters from the SEC which have been rescinded. These regulatory changes may adversely impact the fund’s ability to pursue its investment objective as the fund may not be able to invest in certain funds it would otherwise have invested in without the Rule 12d1-4 restrictions. Additionally, the limitations under Rule 12d1-4 may impact the Advisor’s ability to allocate shares of acquired funds among the fund and other funds in the Advisor’s complex, which could negatively impact the fund. Other funds may also use Rule 12d1-4 to limit or prohibit the fund from investing in them. These limitations could negatively impact fund performance. In order to comply with certain provisions of Rule 12d1-4, notwithstanding anything to the contrary in each fund’s prospectus, summary prospectus, or statement of additional information, each fund generally intends to effect creations for cash rather than in-kind. As a result, an investment in the fund may be less tax-efficient than an investment in an exchange-traded fund that effects its creations only in-kind.

Press Inquiries: Ryan Issakainen, 630-765-8689

Broker Inquiries: Sales Team, 866-848-9727

Analyst Inquiries: Stan Ueland, 630-517-7633

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo

Warrior Met Coal Sets Date for Third Quarter 2022 Earnings Announcement and Investor Conference Call

Warrior Met Coal Sets Date for Third Quarter 2022 Earnings Announcement and Investor Conference Call

BROOKWOOD, Ala.–(BUSINESS WIRE)–
Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its third quarter 2022 investor conference call at 4:30 p.m. ET on Wednesday, November 2, 2022. Warrior Met Coal will release its results following the close of market trading that afternoon.

To participate in the conference call, please call 1-844-340-9047 (domestic) or 1-412-858-5206 (international) 10 minutes prior to the start time and reference the Warrior Met Coal conference call. A webcast of the conference call will be available through the Investor section of the Company’s website, http://investors.warriormetcoal.com, where an archived replay will also be available.

Telephone playback will also be available beginning at 6:30 p.m. ET on November 2, 2022 until 6:30 p.m. ET on November 11, 2022. The replay will be available by calling: 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and entering passcode 1739313.

About Warrior

Warrior is a U.S.-based, environmentally, and socially minded supplier to the global steel industry. It is dedicated entirely to mining non-thermal metallurgical (met) coal used as a critical component of steel production by metal manufacturers in Europe, South America, and Asia. Warrior is a large-scale, low-cost producer and exporter of premium met coal, also known as hard-coking coal (HCC), operating highly efficient longwall operations in its underground mines based in Alabama. The HCC that Warrior produces from the Blue Creek coal seam contains very low sulfur, has strong coking properties and is of a similar quality to coal referred to as the premium HCC produced in Australia. The premium nature of Warrior’s HCC makes it ideally suited as a base feed coal for steel makers and results in price realizations near the Platts Premium LV FOB Australian Index price. For more information, please visit www.warriormetcoal.com.

Analysts and Investors, contact: Dale W. Boyles, (205) 554-6129

News Media, contact: D’Andre Wright, (205) 554-6131

KEYWORDS: Alabama United States North America

INDUSTRY KEYWORDS: Mining/Minerals Manufacturing Coal Natural Resources Energy Other Manufacturing Steel

MEDIA:

Logo
Logo

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.–(BUSINESS WIRE)–
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 35,200 shares of the Company’s common stock at an exercise price per share of $26.15, which was the closing price on October 10, 2022, and restricted stock units to acquire a total of 17,600 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

Inducement PR

Source: Arcus Biosciences

Investor and Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology General Health Health Pharmaceutical Oncology

MEDIA:

Logo
Logo

Paycom Software, Inc. Announces Third Quarter 2022 Earnings Release Date and Conference Call

Paycom Software, Inc. Announces Third Quarter 2022 Earnings Release Date and Conference Call

OKLAHOMA CITY–(BUSINESS WIRE)–Paycom Software, Inc. (“Paycom”) (NYSE:PAYC), a leading provider of comprehensive, cloud-based human capital management software, will release its results for the third quarter ended Sept. 30, 2022, after the market closes on Nov. 1. Paycom will also hold a conference call to discuss results at 5 p.m. (Eastern time) that day.

 

 

 

 

Dial-in #:

 

 

 

 

+1 (833) 470-1428

Intl. Dial-In #:

 

 

 

 

+1 (404) 975-4839

Access Code:

 

 

 

 

010496

Replay #:

 

 

 

 

+1 (866) 813-9403

Intl. Replay #:

 

 

 

 

+1 (929) 458-6194

Replay Access Code:

 

 

 

 

661763

 

The conference call will also be webcast at investors.paycom.com. For those unable to participate, a replay will be available following the conclusion of the earnings call on Nov. 1 through Nov. 7. A web-based archive of the conference call will also be available at the above website.

About Paycom

As a leader in payroll and HR technology, Oklahoma City-based Paycom redefines the human capital management industry by allowing companies to effectively navigate a rapidly changing business environment. Its cloud-based software solution is based on a core system of record maintained in a single database for all human capital management functions, providing the functionality that businesses need to manage the complete employment life cycle, from recruitment to retirement. Paycom has the ability to serve businesses of all sizes and in every industry. As one of the leading human capital management providers, Paycom serves clients in all 50 states from offices across the country. For more information, visit paycom.com.

Investor Relations Contact:

James Samford

[email protected]

KEYWORDS: Oklahoma United States North America

INDUSTRY KEYWORDS: Business Professional Services Technology Software Human Resources

MEDIA:

Logo
Logo

Hippo to Report Third Quarter Financial Results on November 10, 2022

Hippo to Report Third Quarter Financial Results on November 10, 2022

PALO ALTO, Calif.–(BUSINESS WIRE)–
Hippo (NYSE: HIPO), the home insurance group focused on proactive home protection, today announced the company’s third quarter financial results will be released after market close on Thursday, November 10, 2022. The company will host a conference call and live webcast for analysts and investors at 5pm ET/2pm PT on that day. A shareholder letter with the financial results will be accessible from the investor relations section of the company’s website prior to the conference call.

Webcast and Conference Call Details

Date:

Thursday, November 10, 2022

Time:

5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time

Dial-in:

844 200 6205 (U.S.) / +1 929 526 1599 (International)

Conf ID:

082828 

Webcast:

https://events.q4inc.com/attendee/799380823

 

A replay of the webcast will be made available after the call in the investor relations section of the company’s website at https://investors.hippo.com/

About Hippo

Hippo is protecting the joy of homeownership, helping to safeguard customers’ most important financial asset by harnessing the power of real-time data, smart home technology, and a growing suite of home services to deliver proactive home protection.

Hippo Holdings Inc.’s (NYSE: HIPO) operating subsidiaries include Hippo Insurance Services, Hippo Home Care, First Connect Insurance Services, Spinnaker Insurance Company, Spinnaker Specialty Insurance Company, and Mainsail Insurance Company. Hippo Insurance Services is a licensed property casualty insurance agent with products underwritten by various affiliated and unaffiliated insurance companies. For more information, including licensing details, visit http://www.hippo.com.

Forward-looking statement safe harbor

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial results and other operating and performance metrics, our business strategy, the quality of our products and services, and the potential growth of our business. These statements are based on the current expectations of Hippo’s management and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, and many actual events and circumstances are beyond the control of Hippo. These forward-looking statements are subject to a number of risks and uncertainties, including our ability to achieve or maintain profitability in the future; our ability to retain and expand our customer base and grow our business, including our builder network; our ability to manage growth effectively; risks relating to Hippo’s brand and brand reputation; denial of claims or our failure to accurately and timely pay claims; the effects of intense competition in the segments of the insurance industry in which we operate; the availability and adequacy of reinsurance, including at current coverage, limits or pricing; our ability to underwrite risks accurately and charge competitive yet profitable rates to our customers, and the sufficiency of the analytical models we use to assess and predict exposure to catastrophe losses; risks related to our proprietary technology and our digital platform; outages or interruptions or delays in services provided by our third party providers, including our data vendor; risks related to our intellectual property; the seasonal and cyclical nature of our business; the effects of severe weather events and other natural or man-made catastrophes, including the effects of climate change, global pandemics, and terrorism; continued disruptions from the COVID-19 pandemic; any overall decline in economic activity; and the effects of existing or new legal or regulatory requirements on our business, including with respect to maintenance of risk-based capital and financial strength ratings, data privacy and cybersecurity, and the insurance industry generally. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Hippo does not presently know, or that Hippo currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Hippo’s expectations, plans, or forecasts of future events and views as of the date of this press release. Hippo anticipates that subsequent events and developments will cause Hippo’s assessments to change. However, while Hippo may elect to update these forward-looking statements at some point in the future, Hippo specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hippo’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Investors:

Cliff Gallant, VP of Investor Relations

[email protected]

Press:

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Residential Building & Real Estate Construction & Property Insurance

MEDIA:

Logo
Logo

GoodRx Announces Date for Third Quarter 2022 Earnings Release and Conference Call

GoodRx Announces Date for Third Quarter 2022 Earnings Release and Conference Call

SANTA MONICA, Calif.–(BUSINESS WIRE)–GoodRx Holdings Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it will release its third quarter 2022 financial results after U.S. markets close on Tuesday, November 8, 2022. GoodRx management will also hold a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company’s business outlook.

To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where accompanying materials will be posted prior to the conference call.

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.

About GoodRx

GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over $40 billion and are one of the most downloaded medical apps over the past decade.

Investor Contact

GoodRx

Whitney Notaro

[email protected]

Press Contact

GoodRx

Lauren Casparis

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Pharmaceutical Internet General Health Health Health Technology Technology Apps/Applications Other Health

MEDIA:

Logo
Logo

CrossFirst Bankshares, Inc. to Host Third Quarter 2022 Earnings Call

CrossFirst Bankshares, Inc. to Host Third Quarter 2022 Earnings Call

LEAWOOD, Kan.–(BUSINESS WIRE)–
CrossFirst Bankshares, Inc. (Nasdaq: CFB), the parent company of CrossFirst Bank, announced today that management will host a conference call to review third quarter financial results on Tuesday, October 18, 2022, at 11:00 AM E.T. The results are scheduled to be released after the market closes on Monday, October 17, 2022.

To access the event by telephone, please dial (833) 630-1956 at least fifteen minutes prior to the start of the call and request access to the CrossFirst Bankshares call. International callers should dial +1 (412) 317-1837 and request access to the CrossFirst Bankshares call.

This event will also be broadcast live over the internet and can be accessed via the following link: https://edge.media-server.com/mmc/p/6enfwdfg. Please visit the site at least 15 minutes prior to the call to allow time for registration.

For those unable to join the presentation, a replay of the call will be available two hours after the conclusion of the live call. To access the replay, dial (877) 344-7529 and enter the replay access code 6898896. International callers should dial +1 (412) 317-0088 and enter the same access code. A replay of the webcast will also be available for 90 days on the company’s website https://investors.crossfirstbankshares.com/.

ABOUT CROSSFIRST BANKSHARES, INC.

CrossFirst Bankshares, Inc. (Nasdaq: CFB) is a Kansas corporation and a registered bank holding company for its wholly owned subsidiary CrossFirst Bank, which is headquartered in Leawood, Kansas. CrossFirst has nine full-service banking locations in Kansas, Missouri, Oklahoma, Texas, and Arizona that offers products and services to businesses, professionals, individuals, and families.

Heather Worley | CrossFirst Bankshares, Inc.

214.676.4666 | [email protected]

KEYWORDS: United States North America Kansas

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Tripadvisor Announces Chief Financial Officer Succession

PR Newswire


Michael Noonan appointed to role of CFO, effective October 31, 2022


NEEDHAM, Mass.
, Oct. 11, 2022 /PRNewswire/ — Tripadvisor, Inc. (NASDAQ: TRIP) today announced that Ernst Teunissen will retire from his role as Chief Financial Officer to pursue other interests, and that Mike Noonan will join the company as Chief Financial Officer and Senior Vice President, effective October 31, 2022.  Through the first quarter of 2023, Teunissen will be actively engaged with key finance and strategy initiatives as well as facilitating a smooth CFO transition.  

“I would like to thank Ernst, also on behalf of our Board of Directors, for his many valuable contributions over the past seven years, and personally for the counsel he has provided through my own onboarding,” said Matt Goldberg, Chief Executive Officer at Tripadvisor.  “His guidance, especially through the volatile pandemic period, has been key to our strong financial position.  Moreover, his leadership of Viator, TheFork, and Cruise Critic, has driven strong revenue growth for these strategic businesses coming out of the pandemic.”

“I am also excited to announce that Mike Noonan is joining the team as our new CFO.  He brings a dynamic set of experiences across consumer brands and digital business models and a strategic perspective grounded in a deep knowledge of the travel industry, along with a broad and tenured background in corporate finance, long-term financial planning, and capital markets.  We look forward to his leadership and insight as we address the many opportunities to serve our consumers and partners across the travel ecosystem,” continued Goldberg.  “On behalf of all our employees, we welcome him to the Tripadvisor family.”

Noonan joins Tripadvisor with over 30 years of experience in various corporate finance and capital markets roles.  He will join the company from Noom, Inc., a consumer-focused digital health company, where he has served as CFO since October 2020.  Prior to Noom, Noonan served as Senior Vice President of Finance for Booking Holdings, Inc., where he led numerous corporate finance activities such as financial planning and capital budgeting as well as investor relations.  Prior to Booking Holdings, Inc., Noonan worked in several capital markets roles at RBC Capital Markets, NYSE Euronex, J.P. Morgan, and Bear Stearns & Co.  He holds a B.A. in History from Davidson College and an M.B.A. from Duke University.  Noonan will oversee the company’s global finance and related functions.

About Tripadvisor

Tripadvisor, the world’s largest travel guidance platform*, helps hundreds of millions of people each month** become better travelers, from planning to booking to taking a trip. Travelers across the globe use the Tripadvisor site and app to discover where to stay, what to do and where to eat based on guidance from those who have been there before. With more than 1 billion reviews and opinions of nearly 8 million businesses, travelers turn to Tripadvisor to find deals on accommodations, book experiences, reserve tables at delicious restaurants and discover great places nearby. As a travel guidance company available in 43 markets and 22 languages, Tripadvisor makes planning easy no matter the trip type.

The subsidiaries of Tripadvisor, Inc. (Nasdaq:TRIP), own and operate a portfolio of travel media brands and businesses, operating under various websites and apps, including the following websites: www.bokun.io, www.cruisecritic.com, www.flipkey.com, www.thefork.com, www.helloreco.com, www.holidaylettings.co.uk, www.housetrip.com, www.jetsetter.com, www.niumba.com,www.seatguru.com, www.singleplatform.com, www.vacationhomerentals.com, and www.viator.com.

*   Source: SimilarWeb, unique users de-duplicated monthly, June 2022
** Source: Tripadvisor internal log files

TRIP-G

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tripadvisor-announces-chief-financial-officer-succession-301646415.html

SOURCE Tripadvisor

Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research, is scheduled to present at the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on Tuesday, October 18, at 10:30 a.m. PT / 1:30 p.m. ET.

A live webcast of the fireside chat can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology

Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.



Contact:

Carly Scaduto
Senior Director, Media Relations
[email protected]
+1-314-368-5189

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November

– NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy –

       – Data from phase 1b/2 studies in heavily pre-treated patients showcase differentiated safety profile of ADG116 across dosing levels, with repeat dosing both as monotherapy and in combination with anti-PD-1 therapy –

– Posters include new details of responses in monotherapy and combination therapy in tumor types where current anti-CTLA-4 therapy is not approved –

SAN DIEGO and SUZHOU, China, Oct. 11, 2022 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that it will present clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, at the upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place November 8-12 in Boston.

The posters will summarize the comprehensive safety data for ADG116 with repeat dosing as monotherapy, as well as new data supporting its optimal dose selection in combination with two different anti-PD-1 therapies. Additionally, data will show anti-tumor activity in warm and cold tumors, including details of a partial response with monotherapy and a complete response in combination therapy, which were both observed in tumor types where no anti-CTLA-4 therapy is approved.

Details for the poster presentations include:

  • Title: A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObody™ ADG116 Monotherapy and in Combination with Toripalimab (Tori; Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors 
    Date: Thursday, November 10, 2022 (abstract publication on November 7)
    Poster Session: 9:00 a.m. – 9:00 p.m. Eastern Time (ET)
    Onsite Location: Poster Hall
    Abstract Poster Number: 753
  • Title: A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEObody™ ADG116 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update
    Date: Thursday, November 10, 2022 (abstract publication on November 7)
    Poster Session: 9:00 a.m. – 9:00 p.m. ET
    Onsite Location: Poster Hall
    Abstract Poster Number: 773

Both posters will be published on the company’s website at www.adagene.com/pipeline/publications in accordance with the SITC embargo policy on November 10, 2022.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
For more information, please visit: https://investor.adagene.com. Follow Adagene on WeChatLinkedIn and Twitter.

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding certain clinical results of ADG116, the potential implications of clinical results of the product candidate, and Adagene’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of Adagene pipeline candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.



Investor & Media Contact:
Ami Knoefler
Adagene
650-739-9952
[email protected]